{"id":"fd7fc160558a","type":"article","url":"https://hartvaat.nl/2025/09/25/cardiale-cachexie-en-uitkomsten-bij-hartfalen-meta-analyse/","title":"Cardiale cachexie en uitkomsten bij hartfalen: meta-analyse","title_en":"Association between cardiac cachexia and adverse outcomes in patients with heart failure: a meta-analysis of cohort studies.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","cardiale-amyloidose","vrouwen"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2024-325431","source_url":"https://doi.org/10.1136/heartjnl-2024-325431","authors":["Bing Liu","Xinyue Wu","Yuxin Wang","Xinhua Hu"],"significance":5,"published":"2025-09-25","source_date":"2025-09-25","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/palliatief-hartfalen/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"A meta-analysis confirmed that cardiac cachexia in heart failure is associated with significantly higher mortality. This wasting syndrome requires targeted nutritional and exercise interventions as part of comprehensive heart failure management.","created":"2026-07-03T10:31:52Z","updated":"2026-07-03T18:39:18Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Meta-analyse bevestigde dat cardiale cachexie bij hartfalen geassocieerd is met significant hogere mortaliteit. De complicatie vereist gerichte voedings- en bewegingsinterventies.","abstract_original":"BACKGROUND: Cardiac cachexia is a condition characterised by unintentional weight loss and muscle wasting in patients with heart failure. However, there is debate about the prognostic value of cardiac cachexia in these patients. OBJECTIVES: This meta-analysis aimed to evaluate the prognostic value of cardiac cachexia in patients who had heart failure. METHODS: We conducted a thorough literature search of the PubMed, Web of Science and Embase databases until 7 February 2025 to identify studies that examined the prognostic value of cardiac cachexia in patients with heart failure. The outcomes of interest were all-cause mortality and major adverse cardiovascular events (MACEs). The prognostic value of cachexia was determined by pooling the adjusted HR with a 95% CI. RESULTS: Nine studies, including 3821 patients with heart failure, met the inclusion criteria. Depending on the different definitions, the prevalence of cardiac cachexia varied from 11.2% to 37.8% in the included studies. A meta-analysis using a fixed-effects model showed that cardiac cachexia was associated with an increased risk of all-cause mortality (HR 1.59; 95% CI 1.34 to 1.89) and MACEs (HR 2.41; 95% CI 1.50 to 3.85). Subgroup analysis revealed that cardiac cachexia significantly predicted all-cause mortality, regardless of study design, heart failure subtypes, sample sizes, country, patients' age, definitions of cachexia, length of follow-up, baseline body mass index, left ventricular ejection fraction, and whether adjustment for renal function, smoking status, New York Heart Association class or heart failure medications was made. CONCLUSIONS: Cardiac cachexia is associated with a higher risk of all-cause mortality and MACEs in patients with heart failure. Assessing cardiac cachexia may provide valuable prognostic information for these patients."}